Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
Interventions
FYB201 0.5 mg (0.05 mL of 10 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more
Conditions
Ischemic Stroke
Interventions
Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion, Standard medical management
Device · Other
Lead sponsor
Raul Nogueira
Other
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Toledo, Ohio + 1 more
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other · Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Cincinnati, Ohio • Hamilton, Ohio
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms
Interventions
GSK3745417, Dostarlimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
Drug
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

The ShortCut™ Continued Access Study Protocol

NCT06211296
Conditions
Valve-in-valve Procedures, Aortic Stenosis, Coronary; Obstruction
Interventions
Shortcut
Device
Lead sponsor
Pi-cardia
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Thousand Oaks, California • Morristown, New Jersey • New York, New York + 1 more
Conditions
Acute Ischemic Stroke
Interventions
NeVa Stent Retrievers
Device
Lead sponsor
Vesalio
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Thousand Oaks, California • Jacksonville, Florida • Marietta, Georgia + 4 more
Conditions
Retinal Vein Occlusion
Interventions
ANXV
Biological
Lead sponsor
Annexin Pharmaceuticals AB
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more
Conditions
Chronic Kidney Failure, Vascular Graft Occlusion
Interventions
PEG-hirudin
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Aortic Aneurysm, Abdominal, Abdominal Aortic Occlusion, Aortoiliac Occlusive Disease, Aortic Diseases
Interventions
Liposomal bupivacaine, Ropivacaine, Bupivacain
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Funk It Cycle Bites on PMS

NCT05900024
Conditions
Premenstrual Syndrome
Interventions
Funk It Cycle Bites
Other
Lead sponsor
Funk It Wellness
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Plasmodium Falciparum Infection
Interventions
Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Mesa, Arizona • Phoenix, Arizona • Torrance, California + 8 more
Conditions
Peripheral Arterial Disease (PAD)
Interventions
ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Completed Phase 2 Interventional Results available

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
Conditions
Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
Interventions
VP-102 Cantharidin, topical film forming solution
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Plainfield, Indiana + 2 more
Conditions
Coronary Artery Disease, Occlusion of Artery
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Biological
Lead sponsor
Amgen Research (Munich) GmbH
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 8 more
Conditions
Multiple Myeloma (MM)
Interventions
Cemsidomide, Elranatamab
Drug · Biological
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more